Ohio State Navbar

Sign In

Vincent Pompili, MD, FACC

Vincent J. Pompili, MD, FACC
Professor of Internal Medicine
Director, Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories
Director, Cardiovascular Cell-Based Therapies
Wexner Medical Center at The Ohio State University
Phone: (614) 293-4967
Email: vincent.pompili@osumc.edu





Over the past decade, Dr. Pompili and his research group have focused on the development and execution of development of cell-based therapy strategies in the treatment of cardiovascular disease.  Dr. Pompili has specifically worked in the arena of characterization of the function and use of hematopoietic stem cell for induction of angiogenesis in acute and chronic myocardial ischemia.
 
As a pioneer in the translation of bench work to clinical trial in this field, in 2006, Dr. Pompili and his team completed the one of the first clinical trials in the United States studying the safety and early efficacy of marrow-derived CD13 + cells in patients with chronic myocardial ischemia.
 
Over the past 5 years, with funding from the NIH and the Ohio Third Frontier Investment, Dr. Pompili has continued to characterize the use of both marrow-derived and umbilical cord hemangioblasts in clinical application.  Dr. Pompili’s group has also refined and studied techniques for in vitro expansion of hematopoietic stem cells using nanofiber matricies.  The group has also published and executed work on the capacity to genetically modify stem cells to augment functionality
 
Currently here at Ohio State University, Dr. Pompili and his team are leading 3 separate phase I and II clinical trials studying the safety and effects of stem cell therapy in patients after acute myocardial infarction and with chronic limb ischemia.
Team members
Hiranmoy Das, PhD, Senior Scientist
Manjusri Das, Research Scientist
Matt Joseph, Senior Research Associate
Research interests
• Hematopoietic Stem Cell Biology
• Cardiovascular Stem Cell Therapeutics
• Umbilical Cord Blood Derived Stem Cells
• Animal Models of Myocardial Ischemia
• Point of Care Marrow Selection for Cell Therapy
• Stem Cell Expansion
• Genetic  Modification of Stem Cells
Selected Publications
Das H, Joseph M, Abdulhameed N, Mao H, Pompili VJ.  Successful surface-aminated nanofiber expansion of human umbilical cord-derived Cd133+ cells leads to augmentation of angiogenic functionality In Vitro and In Vivo.  Circulation. 2007; 116, 16, suppl S:231

Finney MR, Fanning LR, Kozik M, Matsuyama S, Joseph ME, Goldbert JL, Greco NJ, Haviernik P, Fu P, Pompili VJ, Laughlin MJ.  Augmentation of vasculogenesis by injected human hematopoictic stem cells in response to ischemia follows early activation of innate immune response. Blood. 2007; 110 (11), Part 2: 81B-82B.

George JC, Goldbert J, Joseph M, Abdulhameed N, Crist J, Das H, Pompili VJ.  Transvenous Intramyocardial Cellular Delivery Increases Retention in Comparison to Intracoronary Delivery in a Porcine Model of Acute Myocardial Infarction.  Journal of Interventional Cardiology. 2008; 21: 424-431
Pompili VJ, Crouser ED.  Stem Cell Therapies, a “Magic Bullet” for Cardiomyopathies. Critical Care. 2009; 37 (4): 1487-1489.

Das H, Abdulhameed N, Joseph M, Sakthivel R, Mao HQ, Pompili VJ. Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis.
Cell Transplant. 2009;18(3):305-18

Das H, George JC, Joseph M, Das M, Abdulhameed N, Blitz A, Khan M, Sakthivel R, Mao HQ, Hoit BD, Kuppusamy P, Pompili VJ. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One. 2009 Oct 7;4(10):e7325

Finney MR, Fanning LR, Joseph ME, Goldberg JL, Greco NJ, Bhakta S, Winter DG, Forster M, Scheid PE, Sabe M, Pompili VJ, Laughlin MJ. Umbilical cord blood-selected CD133(+) cells exhibit vasculogenic functionality in vitro and in vivo. Cytotherapy. 2010 Jan;12(1):67-78

Lu J, Pompili VJ, Das H.  Hematopoietic stem cells:  ex vivo expansion and therapeutic potential for myocardial ischemia.  Stem Cells and Cloning:  Advances and Applications.  2010:3-57-68
Adler DS, Lazarus H, Nair R, Goldberg JL, Greco NJ, Lassar T, Laughlin MJ, Das H, Pompili VJ. Safety and efficacy of  bone marrow-derived autologous CD133+ stem cell therapy:  Front Biosci (Elite Ed). 2011 Jan 1;3:506-14.

Kanji S, Pompili VJ, Das H. Maintenance of Hematopoietic Stem Cells. Recent Pat Biotechnol. 2011 Apr 28.